A Phase 1 interventional study of LY3502970 in Healthy and Obese, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 18th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 1, and was the 2nd registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 98th largest by enrollment of the 117 interventional ones that give a count, is one of 10 that started in 2022, is one of 40 in phase 1, and was the 15th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oral doses of 2 milligrams (mg) LY3502970 from days 1-14 and 3 mg LY3502970 from days 15-28 once daily (QD).
Drug: LY3502970
Participants received oral doses of 1 mg LY3502970 from days 1-7, 2 mg LY3502970 from days 8-21 and 3 mg LY3502970 from days 22-28 QD.
Drug: LY3502970
Participants received oral doses of 1 mg LY3502970 from days 1-14, 2 mg LY3502970 from days 15-21 and 3 mg LY3502970 from days 22-28 QD.
Drug: LY3502970
Administered orally.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in one of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events, regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Baseline up to Day 42
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1
PK: AUC\[0-tlast\] of LY3502970
Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1
PK: Cmax of LY3502970
Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 on Day 1
PK: Tmax of LY3502970
Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
PK: AUC[0-tlast] of LY3502970 on Day 28
PK: AUC\[0-tlast\] of LY3502970
Time frame: Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
PK: Cmax of LY3502970 on Day 28
PK: Cmax of LY3502970
Time frame: Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
PK: Tmax of LY3502970 on Day 28
PK: Tmax of LY3502970
Time frame: Day 28 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose)
Pharmacodynamics (PD): Change From Baseline in Body Weight
PD: Change From Baseline in Body Weight
Time frame: Baseline through Day 29
| Milestone | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| Started | 24 | 24 | 24 |
| Received at least one dose of study drug | 24 | 24 | 24 |
| Ly3502970 - 1 mg | 0 | 24 | 24 |
| Ly3502970 - 2 mg | 24 | 24 | 23 |
| Ly3502970 - 3 mg | 24 | 24 | 22 |
| Completed | 24 | 23 | 22 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in one of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events, regardless of causality, will be reported in the Reported Adverse Events module.
| participants | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 20 | 21 | 16 |
PK: AUC\[0-tlast\] of LY3502970
| nanogram hour per milliliter (ng*h/mL) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1 | 117 ± 39 | 66.1 ± 25 | 66.9 ± 30 |
PK: Cmax of LY3502970
| nanograms per milliliter (ng/mL) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1 | 8.40 ± 41 | 4.97 ± 25 | 5.00 ± 34 |
PK: Tmax of LY3502970
| hours (h) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 on Day 1 | 7.03 (4.00 to 8.00) | 6.00 (4.00 to 8.00) | 6.00 (4.00 to 8.00) |
PK: AUC\[0-tlast\] of LY3502970
| ng*h/mL | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| PK: AUC[0-tlast] of LY3502970 on Day 28 | 275 ± 40 | 277 ± 34 | 314 ± 26 |
PK: Cmax of LY3502970
| ng/mL | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| PK: Cmax of LY3502970 on Day 28 | 18.4 ± 43 | 18.4 ± 41 | 21.2 ± 35 |
PK: Tmax of LY3502970
| h | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| PK: Tmax of LY3502970 on Day 28 | 6.00 (4.00 to 12.00) | 6.00 (4.00 to 12.00) | 6.00 (4.00 to 8.00) |
PD: Change From Baseline in Body Weight
| kilograms (kg) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| Pharmacodynamics (PD): Change From Baseline in Body Weight | -4.2 ± 2.5 | -5.5 ± 3.5 | -3.6 ± 1.9 |
Collected over Baseline Through End of Safety Follow-Up (Up To Day 42). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY3502970 Cohort 1 | 0/24 (0%) | 0/24 (0%) | 19/24 (79.2%) |
| LY3502970 Cohort 2 | 0/24 (0%) | 0/24 (0%) | 20/24 (83.3%) |
| LY3502970 Cohort 3 | 0/24 (0%) | 0/24 (0%) | 13/24 (54.2%) |
| Event | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 |
|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 4/24 | 10/24 | 6/24 |
| ConstipationGastrointestinal disorders | 9/24 | 8/24 | 6/24 |
| HeadacheNervous system disorders | 8/24 | 5/24 | 4/24 |
| Weight decreasedInvestigations | 6/24 | 7/24 | 3/24 |
| NauseaGastrointestinal disorders | 4/24 | 6/24 | 2/24 |
| DiarrhoeaGastrointestinal disorders | 4/24 | 5/24 | 2/24 |
| VomitingGastrointestinal disorders | 2/24 | 4/24 | 1/24 |
| EructationGastrointestinal disorders | 2/24 | 0/24 | 3/24 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 3/24 | 0/24 | 1/24 |
| Abdominal distensionGastrointestinal disorders | 1/24 | 1/24 | 2/24 |
All enrolled participants who received at least one dose of study drug.
| Age, Continuous(years) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 | Total |
|---|---|---|---|---|
| Mean | 41.8 ± 14.1 | 42.3 ± 13.4 | 46.1 ± 14.8 | 43.4 ± 14.1 |
| Sex: Female, Male(Participants) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 | Total |
|---|---|---|---|---|
| Female | 5 | 11 | 10 | 26 |
| Male | 19 | 13 | 14 | 46 |
| Ethnicity (NIH/OMB)(Participants) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 10 | 9 | 33 |
| Not Hispanic or Latino | 10 | 14 | 15 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 3 | 11 | 4 | 18 |
| White | 20 | 11 | 17 | 48 |
| More than one race | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | LY3502970 Cohort 1 | LY3502970 Cohort 2 | LY3502970 Cohort 3 | Total |
|---|---|---|---|---|
| United States | 24 | 24 | 24 | 72 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Sep 2022, 3 months.
Results were first posted in May 2026, 3 years 8 months after primary completion.
Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron